Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments - Segment Information (Details)

v3.22.2.2
Note 14 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax $ 7,516     $ 9,116     $ 14,035 $ 44,665  
Grant and other revenue 0     87,266     51,007 436,500  
Revenues, Total 7,516     96,382     65,042 481,165  
Cost of revenue, excluding depreciation and amortization 1,432           1,905    
Inventory Write-down 133,006           133,006 0  
Research and development expenses 1,186,419     1,048,786     4,079,661 3,769,596  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 3,612,747     1,451,309     6,633,793 5,077,058  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 24,703     18,066     69,352 55,672  
Income (loss) from operations [3] (4,950,791)     (2,421,779)     (10,852,675) (8,421,161)  
Other expense, net [4] (757,034)     (14)     (841,853) 358,436  
Net loss (5,707,825) $ (2,999,459) $ (2,987,245) (2,437,836) $ (2,674,040) $ (2,966,892) (11,694,528) (8,078,768)  
Total assets, net of depreciation and amortization 6,258,432           6,258,432   $ 6,644,833
Capital expenditures 14,429     18,042     63,086 20,749  
Income tax expense 0     (16,043)     0 (16,043)  
UNITED STATES                  
Total assets, net of depreciation and amortization 5,979,692     8,742,603     5,979,692 8,742,603  
Non-US [Member]                  
Total assets, net of depreciation and amortization 278,740     216,943     278,740 216,943  
Diagnostics Segment [Member]                  
Grant and other revenue 0     87,266     51,007 436,500  
Revenues, Total 7,516     96,382     65,042 481,165  
Cost of revenue, excluding depreciation and amortization 1,432           1,905    
Inventory Write-down 133,006           133,006    
Research and development expenses 1,073,950     906,677     3,700,528 3,359,190  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 0     0     0 0  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 8,532     6,040     20,613 18,121  
Income (loss) from operations [3] (1,209,404)     (816,335)     (3,791,010) (2,896,146)  
Other expense, net [4] 0     0     0 0  
Net loss (1,209,404)     (822,098)     (3,791,010) (2,901,909)  
Capital expenditures 14,429     0     54,650 0  
Income tax expense       (5,763)       (5,763)  
Diagnostics Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 50,000     185,205     50,000 185,205  
Diagnostics Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization 271,939     216,353     271,939 216,353  
Therapeutics Segment [Member]                  
Grant and other revenue 0     0     0 0  
Revenues, Total 0     0     0 0  
Cost of revenue, excluding depreciation and amortization 0           0    
Inventory Write-down 0           0    
Research and development expenses 112,469     142,109     379,133 410,406  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 745     744     3,746 3,623  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 0     0     0 0  
Income (loss) from operations [3] (113,214)     (142,853)     (382,879) (414,029)  
Other expense, net [4] 0     0     0 0  
Net loss (113,214)     (143,677)     (382,879) (414,853)  
Capital expenditures 0     0     0 0  
Income tax expense       (824)       (824)  
Therapeutics Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 0     0     0 0  
Therapeutics Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization 0     0     0 0  
Corporate Segment [Member]                  
Grant and other revenue 0     0     0 0  
Revenues, Total 0     0     0 0  
Cost of revenue, excluding depreciation and amortization 0           0    
Inventory Write-down 0           0    
Research and development expenses 0     0     0 0  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 3,612,002     1,450,565     6,630,047 5,073,435  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 16,171     12,026     48,739 37,551  
Income (loss) from operations [3] (3,628,173)     (1,462,591)     (6,678,786) (5,110,986)  
Other expense, net [4] (757,034)     (14)     (841,853) 358,436  
Net loss (4,385,207)     (1,472,062)     (7,520,639) (4,762,007)  
Capital expenditures 0     18,042     8,436 20,749  
Income tax expense       (9,457)       (9,457)  
Corporate Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 5,929,692     8,557,398     5,929,692 8,557,398  
Corporate Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization 6,801     590     6,801 590  
License [Member]                  
Revenue from Contract with Customer, Including Assessed Tax 0     9,116     0 44,665  
License [Member] | Diagnostics Segment [Member]                  
Revenue from Contract with Customer, Including Assessed Tax       9,116       44,665  
License [Member] | Therapeutics Segment [Member]                  
Revenue from Contract with Customer, Including Assessed Tax       0       0  
License [Member] | Corporate Segment [Member]                  
Revenue from Contract with Customer, Including Assessed Tax       0       0  
Sales Revenue [Member]                  
Revenue from Contract with Customer, Including Assessed Tax 7,516     $ 0     14,035 $ 0  
Sales Revenue [Member] | UNITED STATES                  
Revenue from Contract with Customer, Including Assessed Tax 0           0    
Sales Revenue [Member] | Non-US [Member]                  
Revenue from Contract with Customer, Including Assessed Tax 7,516           14,035    
Sales Revenue [Member] | Diagnostics Segment [Member] | UNITED STATES                  
Revenue from Contract with Customer, Including Assessed Tax 0           0    
Sales Revenue [Member] | Diagnostics Segment [Member] | Non-US [Member]                  
Revenue from Contract with Customer, Including Assessed Tax 7,516           14,035    
Sales Revenue [Member] | Therapeutics Segment [Member] | UNITED STATES                  
Revenue from Contract with Customer, Including Assessed Tax 0           0    
Sales Revenue [Member] | Therapeutics Segment [Member] | Non-US [Member]                  
Revenue from Contract with Customer, Including Assessed Tax 0           0    
Sales Revenue [Member] | Corporate Segment [Member] | UNITED STATES                  
Revenue from Contract with Customer, Including Assessed Tax 0           0    
Sales Revenue [Member] | Corporate Segment [Member] | Non-US [Member]                  
Revenue from Contract with Customer, Including Assessed Tax $ 0           $ 0    
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($24,703 and $18,066 for the three-month periods ended September 30, 2022 and 2021, and $69,352 and $55,672 for the nine-month periods ended September 30, 2022 and 2021, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.